Samedi, 6 Mars 2021
Dernières nouvelles
Principale » Glaukos Corporation (NYSE:GKOS) CFO Purchases $50064.00 in Stock

Glaukos Corporation (NYSE:GKOS) CFO Purchases $50064.00 in Stock

14 Décembre 2017

Glaukos Corp (NYSE:GKOS) shares traded -4.28% down during most recent session to reach at the closing price of $24.85. Wall Street analysts have a consensus 1.50 recommendation on the stock. Wells Fargo & Company MN owned 3.70% of Glaukos worth $42,003,000 at the end of the most recent quarter.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Shaker Investments LLC OH raised its position in Glaukos by 6.3% in the third quarter. Arrowstreet Capital Limited Partnership now owns 15,300 shares of the medical instruments supplier's stock worth $634,000 after acquiring an additional 6,676 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Glaukos by 740.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier's stock worth $147,000 after buying an additional 3,118 shares during the period. Quantbot Technologies LP increased its holdings in Glaukos by 291.3% in the 3rd quarter. Finally, UBS Asset Management Americas Inc. acquired a new position in shares of Glaukos in the 2nd quarter valued at $274,000. Zacks Investment Research's sales calculations are a mean average based on a survey of research analysts that cover Glaukos.

WARNING: "Glaukos Corporation (GKOS) Expected to Announce Quarterly Sales of $40.81 Million" was first published by StockNewsTimes and is the property of of StockNewsTimes. Stephens reiterated an "overweight" rating and issued a $40.00 price target (down previously from $47.00) on shares of Glaukos in a research report on Monday, November 13th. BidaskClub upgraded Glaukos from a "sell" rating to a "hold" rating in a research report on Friday, September 1st. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Uptrending stocks trade above their moving averages, while downtrending stocks trade below.

In order to gauge which way a stock is trending, you must compare a stock's share price to its moving average. The stock has a market cap of $897.32, a P/E ratio of 216.33 and a beta of 1.02.

Morgan Spurlock Admits Past Sexual Misconduct 'I am Part of the Problem'
In a tweet after his blog post, Spurlock said he was "seeking help". We took off our clothes. 'I didn't know what to do, ' he writes. I tried to comfort her. "She believed she was raped".

This stock (GKOS) is ahead of its 52-week low with 6.02%. The consensus mean EPS for the current quarter is at $0.01 derived from a total of 8 estimates from the analysts who have weighed in on projected earnings. The firm had revenue of $40.41 million for the quarter, compared to analyst estimates of $38.69 million. Glaukos had a positive return on equity of 3.50% and a negative net margin of 0.64%. During the same period in the previous year, the company posted $0.03 earnings per share. equities analysts forecast that Glaukos Corporation will post -0.03 earnings per share for the current fiscal year.

In other Glaukos news, CEO Thomas William Burns sold 73,788 shares of the stock in a transaction dated Thursday, September 7th. The shares were purchased at an average cost of $23.84 per share, for a total transaction of $50,064.00. Following the acquisition, the chief financial officer now directly owns 102,100 shares of the company's stock, valued at $2,434,064. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Glaukos Corporation (NYSE:GKOS) closed its last session at $24.85. The correct version of this report can be accessed at

Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma.